Dana Pizzuti - 21 Dec 2023 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role: Chief Med and Dev Officer
Signature: /s/ Marc Wilson, as attorney-in-fact
Issuer symbol: CRNX
Transactions as of: 21 Dec 2023
Net transactions value: -$169,427
Form type: 4
Filing time: 22 Dec 2023, 18:45:18 UTC
Previous filing: 05 Apr 2023
Next filing: 04 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRNX	Common Stock	Options Exercise	$161,857	+9,583	+162%	$16.89	15,494	21 Dec 2023	Direct	F1
transaction	CRNX	Common Stock	Sale	$331,284	-9,583	-62%	$34.57	5,911	21 Dec 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRNX	Non-qualified stock option (Right to Buy)	Options Exercise	$0	-9,583	-4.2%	$0.000000	220,417	21 Dec 2023	Common Stock	9,583	$16.89	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 1,411 shares acquired under the Issuer's Employee Stock Purchase Plan.
F2	The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $34.57 per share. The range of sales prices on the transaction date was $34.50 to $34.67 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F3	The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.